O3-2-6SHORT HYDRATION VERSUS CONTINUOUS HYDRATION IN CHEMOTHERAPY CONTAINING INTERMEDIATE- TO HIGH-DOSE CISPLATIN

Abstract Background and aims: The efficacy of the short hydration regimen was reported in chemotherapy containing intermediate- to high-dose cisplatin, and the use of outpatient chemotherapy containing cisplatin with short hydration has been widespread in recent years. We have provided outpatient chemotherapy containing cisplatin with the short hydration regimen since July 2012. The aim of this study was to evaluate the safety and efficacy of the short hydration regimen. Methods: We compared patients with gastric cancer, lung cancer, and urothelial cancer who received outpatient chemotherapy containing cisplatin (≥ 60 mg/m2/cycle) with the short hydration regimen since July 2012 (n = 13) with those who received hospital chemotherapy with continuous hydration between April 2011 and June 2012 (n = 17) in our hospital. To assess the incidence of cisplatin nephrotoxicity and the effect of the treatment, serum creatinine and creatinine clearance levels were monitored and relative dose intensity (RDI) was calculated. Results: There was no difference between the 2 groups with respect to the background factors. Grade 2 or higher acute kidney injury occurred in 2 patients in the continuous hydration group and in no patient in the short hydration group; 1 patient discontinued treatment on account of nephrotoxicity. There was no difference between the 2 groups in the average value of maximum creatinine increment (0.14 mg/dl vs. 0.32 mg/dl; p = 0.43) and maximum clearance decrement (10.9 ml/min vs. 18.3 ml/min; p = 0.28). RDI in the short hydration group was higher than that in the continuous hydration group (89.5% vs. 80.3%; p Conclusions: The short hydration regimen in outpatient chemotherapy containing intermediate- to high-dose cisplatin is as safe as the continuous hydration regimen, and increases the efficacy with the convenience of chemotherapy scheduling.